Evidence map›Paper›PMID 26480810›Full record

Trial reportPhotodiagnosis and photodynamic therapy2015

Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.

S C Kanick, S C Davis, Y Zhao, K L Sheehan, T Hasan, E V Maytin, B W Pogue, M S Chapman

2 registry-linked trialsOpen access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Photodiagnosis and photodynamic therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03805737 nacompletednot on this mapstarted 2019, after this paper: background citation

Indoor Daylight Photo Dynamic Therapy (PDT) for Actinic Keratosis

TypeinterventionalSponsorDartmouth-Hitchcock Medical CenterRan2019 to 2021Enrolled43ConditionsActinic KeratosisArmsAmulez and sunlight, Amulez and red light treatment
NCT04223570 completednot on this mapstarted 2022, after this paper: background citation

Portable Measurement of Protoporphyrin IX in the Skin

TypeobservationalSponsorDartmouth-Hitchcock Medical CenterRan2022 to 2025Enrolled219ConditionsPhotodynamic Therapy, Protoporphyrin IXArmsPortable Apple Smart Phone Protoporphyrin IX Spectrometer Camera
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Redox processes in the treatment of advanced skin cancers.Clinical & experimental metastasis · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

S C KanickThayer School of Engineering, Dartmouth College, Hanover, USA; Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon NH, USA. Electronic address: stephen.c.kanick@dartmouth.edu.
S C DavisThayer School of Engineering, Dartmouth College, Hanover, USA; Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon NH, USA.
Y ZhaoThayer School of Engineering, Dartmouth College, Hanover, USA.
K L SheehanDepartment of Surgery, Dartmouth Hitchcock Medical Center, Lebanon, USA.
T HasanWellman Center for Photomedicine, Massachusetts General Hospital, Boston, USA.
E V MaytinWellman Center for Photomedicine, Massachusetts General Hospital, Boston, USA; Biomedical Engineering, Cleveland Clinic, Cleveland, USA.
B W PogueThayer School of Engineering, Dartmouth College, Hanover, USA; Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon NH, USA; Department of Surgery, Dartmouth Hitchcock Medical Center, Lebanon, USA; Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, USA.
M S ChapmanDepartment of Surgery, Dartmouth Hitchcock Medical Center, Lebanon, USA.
Dartmouth College · USDartmouth–Hitchcock Medical Center · USCleveland Clinic · USMassachusetts General Hospital · US

Funding

Small Molecule Enhancers of Photodynamic Therapy for Skin CancerP01CA084203 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Tayyaba Hasan · 2001 to 2026
$27.9M
OPTICAL CHERENKOV IMAGING DOSIMETRY IN HUMAN RADIOTHERAPYR01EB023909 · NIBIB · UNIVERSITY OF WISCONSIN-MADISON · PI GLADSTONE, DAVID J., JARVIS, LESLEY A · 2017 to 2024
$4.4M
Quantitative optical dosimetry of magnetic nanoparticle cancer treatmentsK25CA164248 · NCI · DARTMOUTH COLLEGE · PI KANICK, STEPHEN CHAD · 2013 to 2015
$498k
NCI NIH HHS K25 CA164248NCI NIH HHS K25CA164248NCI NIH HHS P01 CA084203NCI NIH HHS P01CA084203NIBIB NIH HHS R01 EB023909
6 · The paper itself

Abstract

backgroundAlthough aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX) photodynamic therapy (PDT) is an effective FDA-approved therapy for actinic keratosis (AK), a substantial fraction of patients (up to 25%) do not respond to treatment. This study examined the feasibility of using pre-treatment measurements of PpIX concentration in AK lesions to predict response of ALA-PpIX PDT.

methodsA non-invasive fiber-optic fluorescence spectroscopy system was used to measure PpIX concentration in patients undergoing standard-of-care ALA-PDT for AK. All patients provided assessments of pain at the time of treatment (n=70), and a subset reported pain and erythema 48-76 h after treatment (n=13).

resultsPpIX concentration was significantly higher in lesions of patients reporting high levels of pain (VAS score ≥5) immediately after treatment vs. patients reporting pain scores below VAS=5 (p<0.022) (n=70). However, pain was not an exclusive indicator of PpIX concentration as many patients with low PpIX concentration reported high pain. In a subpopulation of patients surveyed in the days after treatment (n=13), PpIX concentration measured on the day of treatment was uncorrelated with pain-reported immediately after treatment (r=0.17, p<0.57), but positive correlations were found between PpIX concentration and patient-reported pain (r=0.55, p<0.051) and erythema (r=0.58, p<0.039) in the 48-72 h following treatment.

conclusionsThese data suggest that in vivo optical measurements of PpIX concentration acquired before light delivery may be an objective predictor of response to ALA-PpIX PDT. Identification of non-responding patients on the day of treatment could facilitate the use of interventions that may improve outcomes.

Indexed as

Aminolevulinic AcidBiomarkersDose-Response Relationship, DrugErythemaFemaleHumansKeratosis, ActinicMalePainPhotochemotherapyPhotosensitizing AgentsProtoporphyrinsSpectrometry, FluorescenceAminolevulinic AcidBiomarkersPhotosensitizing Agentsprotoporphyrin IXProtoporphyrinsActinic keratosisOptical dosimetryPhotodynamic therapy

Identifiers

PMID26480810
PMCPMC4684466
OpenAlexW2105562288

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.